ABX-002

DRUG4 trials

Sponsors

Autobahn Therapeutics, Inc.

Conditions

Bipolar Disorder DepressionHealthyMDDMajor Depressive Disorder

Phase 1

SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects

CompletedNCT05528315

Autobahn Therapeutics, Inc.MDD

Start: 2022-10-12End: 2023-09-13Updated: 2023-09-15

ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants

CompletedNCT07652697

Autobahn Therapeutics, Inc.Healthy

Start: 2025-01-02End: 2025-02-17Updated: 2026-06-17

Phase 2

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

RecruitingNCT06633016

Autobahn Therapeutics, Inc.Major Depressive Disorder

Start: 2024-09-20End: 2026-06-01Target: 230Updated: 2026-01-20

Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults

Active, not recruitingNCT06869187

Autobahn Therapeutics, Inc.Bipolar Disorder Depression

Start: 2025-03-28End: 2026-09-24Target: 35Updated: 2026-05-26